www.pharmtech.com

www.pharmtech.com
Share

www.pharmtech.com

 •  January 2

Policy makers look to boost generic drugs, curb opioid abuse, and maintain incentives for innovation. Concerns that high and rising drug prices hinder patient treatment will continue to shape pharmaceutical markets in what promises to be a tumultuous year in Washington. Policy makers will weigh access to medicines with the desire to encourage...

www.pharmtech.com

 •  October 23, 2017

Applying the right formulation strategies early in the drug development process can help avoid costly late-stage failures. Improving R&D productivity continues to be a key challenge for the pharmaceutical industry. There is increasing pressure to speed up drug development and make it more cost-effective. Companies want to ensure that their most...

www.pharmtech.com

 •  October 16, 2017

The pharmaceutical industry is under tremendous pressure to make drug development faster and cheaper. “There is a need for better treatments that show real-world efficacy, but the price has to be acceptable to payers and at the same time offer good returns to the developing company,” says Will Downie, Catalent’s senior vice-president of Global...

www.pharmtech.com

 •  September 20, 2017

The enormous cost associated with drug development is one of the biggest challenges for pharmaceutical manufacturers. With an estimated cost of $2.6 billion and more than 10 years (1) to develop and test a drug candidate, the pharmaceutical industry is constantly looking for new efficiencies that will save time, money, research, and resources. One...

www.pharmtech.com

 •  May 3, 2017

FDA regulation of drug-biologic-device combination products has been a tricky business, with manufacturers struggling to contend with unfamiliar rules and development strategies for these complex therapies. The rise of personalized medicine and technological advances have led to new types of drug-eluting stents, prefilled syringes, autoinjectors,...

www.pharmtech.com

 •  February 14, 2017

As you were browsing http://www.pharmtech.com something about your browser made us think you were a bot. There are a few reasons this might happen: You're a power user moving through this website with super-human speed. You've disabled JavaScript in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing...

www.pharmtech.com

 •  February 13, 2017

Manufacturers and FDA officials are pressing for Congressional action on the latest version of the Prescription Drug User Fee Act (PDUFA VI) and highlighting key provisions in the program designed to accelerate drug development and application review. Congressional staffers have set a goal for finalizing user fee reauthorization measures by June,...